En

November 20, 2019Nottingham, United Kingdom

It has been over twenty years since Lipinski published his work determining the properties of drug molecules associated with good solubility and permeability. Since then, there have been a number of additions and expansions to these “rules”. There has also been keen interest in the application of these guidelines in the drug discovery process and how these apply to new emerging chemical structures such as macrocycles. 

This symposium will bring together researchers from a number of different areas of drug discovery and will provide a historical overview of the use of Lipinski’s rules, as well as looking to the future and how we use these rules in the changing drug compound landscape. 

Features of the Meeting

  • Historical look at the use of the Rule of Five
  • New parameters used in drug discovery
  • Look forward to the next 20 years
  • Panel discussions in each session
  • Plenary speakers, poster session, and drinks reception

For more information please contact: maggi@maggichurchouseevents.co.uk

November 22, 2019Brussels, Belgium

The Medicinal Chemistry Divisions of the two Belgian Chemical Societies, the Koninklijke Vlaamse Chemische Vereniging (KVCV) and the Société Royale de Chimie (SRC), are organising every year an international one-day symposium with the aim to update participants on selected areas of pharmaceutical research by specialists in their respective field. 

MedChem 2019 will be held on Friday November 22, 2019, in Brussels. The programme of the day will include six invited lectures and three oral communications selected from submitted abstracts.

This year, the symposium will delve into the developments in the therapeutic use of peptides.

Confirmed Speakers:

  • Prof. Fernando ALBERICIO (UNIVERSITY OF KWAZULU-NATAL, Durban , South Africa)
    Linkers for Peptide Conjugation
  • Prof. Christian F.W. BECKER (UNIVERSITY OF VIENNA, Wien, Austria)
    Synthetic Immune System Engagers – a Peptide-based Approach to Immune-oncology
  • Prof. Eric MARSAULT (UNIVERSITY OF SHERBROOKE, Sherbrooke, Canada)
    Macrocyclization as an Enabling Tool Toward Novel Peptide Drug Candidates
  • Prof. Kristian STROMGAARD (UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark) 
    Targeting Receptor Complexes: A New Dimension in Drug Discovery
  • Dr Meritxell TEIXIDO (INSTITUTE FOR RESEARCH IN BIOMEDICINE, Barcelona, Spain)
    Gate2Brain, Opening the Gate to CNS Therapies

Deadline for abstract submission and early bird fee is October 10, 2019!

For more information please contact: secretariat@ldorganisation.com

Organised by:
  • Medicinal and Bioorganic Chemistry Division of Royal Flemish Chemical Society (KVCV) (Belgium)
  • Société Royale de Chimie (SRC), Medicinal Chemistry Division (Belgium)

January 19-23, 2020St. Anton, Austria

The “Alpine Winter Conference on Medicinal and Synthetic Chemistry” exposes attending scientists to cutting edge synthetic and medicinal chemistry as well as latest developments in technologies that foster innovation in drug discovery. The main target audience for this highly interdisciplinary meeting will include medicinal and synthetic chemists, as well as related drug discovery disciplines from both industry and academia as well as graduate/undergraduate students and postdocs.

In the spirit of Keystone and Gordon conferences as well as the MBCF (Medicinal and Bioorganic Chemistry Foundation) conference in Steamboat Springs, the format of this meeting provides ample opportunity for attendees to informally interact. The aim is to strengthen existing networks and create new contacts.

The Conference topics will include:

  • Accelerating Drug Discovery by Intelligence Augmentation
  • Drug Discovery Tales
  • Frontiers of Synthetic Chemistry
  • Innovation and Inspiration from Natural Products
  • Predictive ADME Sciences: Striking a Balance Between in Silico and Experimental Work?
  • Protein Degradation: New Rules for Drug Discovery
  • Structure and Biophysics - Companions for Medicinal Chemistry
  • Targeted Delivery - Strategies to Help your Drug Substances get to the Right Place

Deadline for abstract submission and early bird fee is October 16, 2019!

For more information please contact: secretariat@ldorganisation.com

April 14-15, 2020San Francisco, United States

The identification of potential new therapeutic agents is met with significant challenges in preclinical discovery and development.  Both efficacy and safety endpoints must be adequately assessed prior to testing a new investigational agent in humans.  Perhaps the most challenging part of drug discovery is the mitigation of safety risks that arise during most drug discovery optimization efforts.  In order to design and make safer drug candidates, medicinal chemists work with cross-functional drug discovery partners to understand, assess and mitigate safety risks associated with potential new drug candidates.  Successful drug discovery teams will properly design and execute experiments that can best assess and discharge risks prior to first human dose (FHD).  This must be accomplished in the context of anticipated human drug exposures and patient risk-benefit analysis.  Through the lens of modern medicinal chemistry, this course explores the current best practices and methods used to identify, understand and mitigate common preclinical safety risks from both a strategic and tactical perspective.  Importantly, the course also describes proactive approaches that can help medicinal chemists avoid many safety issues and deliver safer small molecule drug candidates.  A key objective of the course is to improve medicinal chemist’s preparedness for participation and leadership on cross-functional drug discovery teams.

Course Outline:

  • Principles of toxicology and safety assessment.
  • The Investigational New Drug (IND) application.
  • Target assessment, predictive toxicology and in silico methods.
  • Preferred drug properties to minimize toxicological risks.
  • Common off-target safety concerns and mitigation.
  • Managing on-target safety concerns.
  • Pharmacokinetics in preclinical safety assessment.
  • Drug metabolism and bioactivation.
  • Toxicophores and Structure Alerts.
  • Mechanisms and mitigation strategies for Drug-Induced Liver Injury (DILI).
  • Preclinical safety biomarkers and translation to the clinic.
  • Clinical candidate selection and FHD enablement.

For more information contact: sciup@scientificupdate.co